Mayne Knocked Back Again On US NuvaRing Rival
Pledges To Address Issues Raised In FDA Complete Response Letter
Mayne Pharma has received a further setback in its attempt to bring a generic version of NuvaRing to the US market after the FDA issued the firm with another complete response letter.
